What is NovoCure Ltd Annual Revenue?

NovoCure Ltd Annual Revenue rose 18.82%, in the last year to $605.22 M. Its sector's average revenue growth for the last fiscal year was 8.73%.

What is NovoCure Ltd Annual Net Profit?

NovoCure Ltd Annual Net Profit rose 18.55% in the last year to $168.63 M. Its sector's average net profit growth for the last fiscal year was 3.61%.

What is NovoCure Ltd Price to Earning Ratio?

NovoCure Ltd Price to Earning Ratio is -12.59, which is negative.

What is NovoCure Ltd Stock Price?

NovoCure Ltd Stock Price rose 39.8% and outperformed its sector by 32.14% in the past year.

What is NovoCure Ltd Quarterly Revenue?

NovoCure Ltd Quarterly Revenue rose 20.54% YoY to $161.27 M. Its sector's average revenue growth YoY for the quarter was 8.58%.

What is NovoCure Ltd Quarterly Net profit?

NovoCure Ltd Quarterly Net profit fell 40.02% YoY to $65.92 M. Its sector's average net profit growth YoY for the quarter was 27.3%.

What is NovoCure Ltd Debt to Equity Ratio?

NovoCure Ltd Debt to Equity Ratio of 1.9 is higher than 1. This implies that company assets are financed through debt.

What is NovoCure Ltd Return on Equity(ROE)?

NovoCure Ltd Return on Equity(ROE) for the last financial year was -46.67%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is NovoCure Ltd Mutual Fund Holding?

NovoCure Ltd Mutual Fund Holding decreased by 1.88% in the last quarter to 74.05.

What is NovoCure Ltd Promoter Share Holding?

NovoCure Ltd Promoter Share Holding increased by 0.91% in the most recent quarter to 2.25%.

What is NovoCure Ltd Interest Coverage Ratio?

NovoCure Ltd Interest Coverage Ratio is -11.68, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is NovoCure Ltd Institutional Holding?

NovoCure Ltd Institutional Holding remained the same in the last quarter at 84.77%.

How is the NovoCure Ltd today?

The NovoCure Ltd today is trading in the down by -0.21% at 19.32.

How has NovoCure Ltd performed historically?

The NovoCure Ltd is currently trading down -0.21% on an intraday basis in the past week the index fell -9.38%. The index has been down -38.74% in the past quarter and rose 39.80% in the past year. You can view this in the overview section.

NovoCure Ltd XNAS: NVCR

NovoCure Ltd Live Share Price Today, Share Analysis and Chart

Name: NovoCure Ltd: Is Infosys Ltd. worth buying?
Item: NovoCure Ltd
Rating: 1.60083325
Author: Trendlyne DVM scores

Momentum Trap

Download real time

19.32 -0.04 (-0.21%)

43.39% Fall from 52W High

528.4K XNAS Volume

XNAS 19 Mar, 2025 5:30 PM (EDT)

NovoCure Ltd Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	2,123.6
PE TTM Negative PE TTM Unavailable in chosen country	-12.6
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.7
Price to Book Below industry Median Unavailable in chosen country	5.9
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	84.8
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	20.5
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	18.8
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-40
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	18.6
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-39.3
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-28.2
Piotroski Score Below industry Median Unavailable in chosen country	3
Rel Perf vs Sector quarter% Unavailable in chosen country	-41.7
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-46.7
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-14.1

All financials are in USD Million and price data in USD

Low Financial Strength

33.3 / 100

Expensive Valuation

11.0 / 100

Technically Neutral

50.4 / 100

Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 84%

7 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

NovoCure Ltd Stock Price Analysis

Day Price Range -0.2% 1 Day return Unavailable in chosen country	19.3 (LTP) 19.119.6 LowHigh
Week Price Range -9.4% 1 Week return Unavailable in chosen country	19.3 (LTP) 18.821.6 LowHigh
Month Price Range -12.4% 1 Month return Unavailable in chosen country	19.3 (LTP) 17.122.3 LowHigh
52 Week Price Range 39.8% 1 Year return Unavailable in chosen country	19.3 (LTP) 11.734.1 LowHigh

View full Share Price History

NovoCure Ltd Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

NovoCure Ltd's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-1.6

Avg. Estimate

-2

Low Estimate

-2.8

High Estimate

-1.7

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 31.4% in FY25

Consensus Recommendation

7 ANALYST Recommendations

BUY

The consensus recommendation from 7 analysts for NovoCure Ltd is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

NovoCure Ltd Stock Analysis

NovoCure Ltd stock analysis with key metrics, changes, and trends.

NovoCure Ltd Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$605.22 M	18.82%	positive	Annual Revenue rose 18.82%, in the last year to $605.22 M. Its sector's average revenue growth for the last fiscal year was 8.73%.
Annual Net Profit	$168.63 M	18.55%	positive	Annual Net Profit rose 18.55% in the last year to $168.63 M. Its sector's average net profit growth for the last fiscal year was 3.61%.
Price to Earning Ratio	-12.59	-	negative	Price to Earning Ratio is -12.59, which is negative.
Stock Price	$19.32	39.8%	positive	Stock Price rose 39.8% and outperformed its sector by 32.14% in the past year.
Quarterly Revenue	$161.27 M	20.54%	positive	Quarterly Revenue rose 20.54% YoY to $161.27 M. Its sector's average revenue growth YoY for the quarter was 8.58%.
Quarterly Net profit	$65.92 M	40.02%	negative	Quarterly Net profit fell 40.02% YoY to $65.92 M. Its sector's average net profit growth YoY for the quarter was 27.3%.
Debt to Equity Ratio	1.9	-	negative	Debt to Equity Ratio of 1.9 is higher than 1. This implies that company assets are financed through debt.
Return on Equity(ROE)	-46.67 %	-46.67%	negative	Return on Equity(ROE) for the last financial year was -46.67%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	74.05 %	-1.88%	negative	Mutual Fund Holding decreased by 1.88% in the last quarter to 74.05.
Promoter Share Holding	2.25 %	0.91%	positive	Promoter Share Holding increased by 0.91% in the most recent quarter to 2.25%.
Interest Coverage Ratio	-11.68	-	negative	Interest Coverage Ratio is -11.68, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	84.77 %	0%	neutral	Institutional Holding remained the same in the last quarter at 84.77%.

VIEW LESS

Loading data..

NovoCure Ltd - Company Profile

What does NovoCure Ltd do?

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Gross Remuneration

2024

Gross Remuneration

Year

NovoCure Ltd Live Share Price Today, Share Analysis and Chart

43.39% Fall from 52W High

NovoCure Ltd Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

NovoCure Ltd Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

NovoCure Ltd Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

NovoCure Ltd's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to reduce by 31.4% in FY25

Consensus Recommendation

The consensus recommendation from 7 analysts for NovoCure Ltd is BUY

NovoCure Ltd Stock Analysis

NovoCure Ltd stock analysis with key metrics, changes, and trends.

Annual Revenue rose 18.82%, in the last year to $605.22 M. Its sector's average revenue growth for the last fiscal year was 8.73%.

Annual Net Profit rose 18.55% in the last year to $168.63 M. Its sector's average net profit growth for the last fiscal year was 3.61%.

Price to Earning Ratio is -12.59, which is negative.

Stock Price rose 39.8% and outperformed its sector by 32.14% in the past year.

Quarterly Revenue rose 20.54% YoY to $161.27 M. Its sector's average revenue growth YoY for the quarter was 8.58%.

Quarterly Net profit fell 40.02% YoY to $65.92 M. Its sector's average net profit growth YoY for the quarter was 27.3%.

Debt to Equity Ratio of 1.9 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE) for the last financial year was -46.67%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 1.88% in the last quarter to 74.05.

Promoter Share Holding increased by 0.91% in the most recent quarter to 2.25%.

Interest Coverage Ratio is -11.68, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding remained the same in the last quarter at 84.77%.

NovoCure Ltd - Company Profile

What does NovoCure Ltd do?

NovoCure Ltd Management structure

Mr. Pritesh Shah

Chief Growth Officer

Mr. Francis Leonard

Executive Vice President and President Novocure Oncology

Dr. Nicholas Leupin, M.D.,PhD

Chief Medical Officer

Mr. Wilhelmus C. M. Groenhuysen

Chief Operating Officer

Mr. Asaf Danziger

Chief Executive Officer and Director

Ms. Ashley Cordova

Chief Executive Officer

NovoCure Ltd Board of directors

Mr. Asaf Danziger